AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02143687 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sham oxygen (room air)
Description: Sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights at 490 m and 2048 m
Study NCT00187551 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interruption of enfuvirtide
Description: treatment interruption
Study NCT00187551 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enfuvirtide interrupton
Description: enfuvitide will be interrupted in patients harboring resistant virus
Study NCT04700943 — intervention group
Intervention type: PROCEDURE
Intervention: Regional awake anesthesia
Description: We want to assess the impact of regional anesthesia on diaphragmatic function in patients undergoing Video-assisted thoracoscopic surgery pulmonary biopsy in interstitial lung disease
Study NCT02471443 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery for severe endometriosis
Description: Consecutive patients undergoing excisional surgery for severe endometriosis with bowel involvement
Study NCT01126424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin
Description: tablet
Study NCT01126424 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxybutynin
Description: capsule
Study NCT01126424 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablet
Study NCT00426270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octagam 10%
Description: Octagam 10% was supplied as a ready-to-use solution in glass bottles.
Study NCT00047827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micafungin
Description: IV
Study NCT00047827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Amphotericin B
Description: IV
Study NCT04980729 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acetabular reconstruction after tumor resection.
Description: In the template-guided group (n = 10), a navigation template was designed and applied to assist acetabular reconstruction. In the traditional operation group (n = 14), the patients underwent the same surgery but without the navigation template. To compare the displacement of the hip rotation center before and after surgery between the two groups, an innovative method based on pelvic CT was developed and a validation group of cases was used to assess the effectiveness of this measurement approach. In the validation group (n = 12), patients undergoing periacetabular puncture or curettage without hip joint reconstruction were included. The displacements for the validation group were calculated and compared with 0 cm, the theoretical value. Subsequently, the displacements between the template-guided group and the traditional operation group were compared.
Study NCT04980729 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acetabular reconstruction after tumor resection.
Description: In the template-guided group (n = 10), a navigation template was designed and applied to assist acetabular reconstruction. In the traditional operation group (n = 14), the patients underwent the same surgery but without the navigation template. To compare the displacement of the hip rotation center before and after surgery between the two groups, an innovative method based on pelvic CT was developed and a validation group of cases was used to assess the effectiveness of this measurement approach. In the validation group (n = 12), patients undergoing periacetabular puncture or curettage without hip joint reconstruction were included. The displacements for the validation group were calculated and compared with 0 cm, the theoretical value. Subsequently, the displacements between the template-guided group and the traditional operation group were compared.
Study NCT04980729 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Acetabular reconstruction after tumor resection.
Description: In the template-guided group (n = 10), a navigation template was designed and applied to assist acetabular reconstruction. In the traditional operation group (n = 14), the patients underwent the same surgery but without the navigation template. To compare the displacement of the hip rotation center before and after surgery between the two groups, an innovative method based on pelvic CT was developed and a validation group of cases was used to assess the effectiveness of this measurement approach. In the validation group (n = 12), patients undergoing periacetabular puncture or curettage without hip joint reconstruction were included. The displacements for the validation group were calculated and compared with 0 cm, the theoretical value. Subsequently, the displacements between the template-guided group and the traditional operation group were compared.
Study NCT02081209 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Zeltiq System
Description: Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
Study NCT03595098 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Based Cognitive Behavioural Therapy
Description: Family Based Cognitive Behavioural Therapy (FCBT) focuses on the interrelation between thought, emotion, and behaviour, Exposure and Response Prevention, family involvement, homework assignments, and formulating of specific goals for the child. The important, active components is Exposure and Response Prevention. It involves exposing the child to a feared object, situation or thought, and preventing the child from carrying out compulsions to show the child that distress/anxiety can decrease or disappear without performing rituals.
Study NCT03595098 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family Based Psychoeducation/Relaxation Training
Description: Family-based Psychoeducation/Relaxation Training (FPRT) as an active control matches the experimental intervention as closely as possible, many elements of the control intervention are similar to FCBT. The main and intended difference between the two approaches is the absence of the Exposure and Response Prevention component, which is deemed the most effective treatment for OCD.
Study NCT00846599 — intervention group
Intervention type: OTHER
Intervention: Omega-3 study meal
Description: Participant will eat a study meal high in omega-3 fatty acids.
Study NCT00846599 — intervention group
Intervention type: OTHER
Intervention: Saturated fat study meal
Description: Participant will eat a study meal high in saturated fat.
Study NCT01283347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-DTBZ
Description: During this study, subjects will receive a single i.v. administration of approximately 10 mCi 18F-FP-(+)-DTBZ immediately prior to imaging.~The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG
Study NCT01117870 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulsed Radiofrequency
Description: 120 seconds at 42 degrees celsius
Study NCT01117870 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Needle will be continuously stimulated at a low voltage to give a sensation of PRF application.
Study NCT01040819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Patients will receive PIO 15 mg/d for one month, then 55 patients continue with the same dose for one additional month, and in 55 patients the dose will be increased to 30 mg/d for an additional one month. Other non-diabetes drugs should not be changed. Other hypoglycemic agents, including insulin may be adjusted, if clinically indicated. NSAID, COX2 inhibitors, aspirin >162 mg/d, steroids and prostaglandin analogs will be prohibited.
Study NCT04204603 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets for oral administration
Study NCT04055532 — intervention group
Intervention type: OTHER
Intervention: Neuraceq
Description: Neuraceq is a radioactive isotope used for Amyloid-beta-PET/CT scans.
Study NCT05080985 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TPVB
Description: 20 ml 0.375 % bupivacaine was injected between superior costotransverse ligament and pleura.
Study NCT05080985 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESPB
Description: 20 ml 0.375 % bupivacaine was injected between deep fascia of the erector spinae muscle and transverse process.
Study NCT05080985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain
Description: 20 ml 0.375 % bupivacaine was injected
Study NCT03073707 — intervention group
Intervention type: BEHAVIORAL
Intervention: Sample collection
Description: Stool samples will be collected from household members of children diagnosed with NTS infection. In addition stool samples of animals and rats will be collected as well as samples of the water supply of the household.
Study NCT01951300 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Gallium-68 citrate
Description: Single intravenous bolus injection of 200 MBq of Gallium-68 citrate radiopharmaceutical
Study NCT01592955 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EYEOP1
Description: Cyclocoagulation using High Intensity Focused Ultrasound with EYEOP1 device
Study NCT01260909 — intervention group
Intervention type: DEVICE
Intervention: Real-time kV/MV Prostate Imaging
Description: The kV images will be acquired using onboard kV X-Ray imaging system existing in the clinical linear accelerator (LINAC).
Study NCT02690727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP6530
Description: Single oral dose
Study NCT03157089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Film-coated tablet
Study NCT03157089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: Solution for infusion
Study NCT04715490 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Multimedia Symptom Management Program Intervention
Description: The program is composed of two parts: 1) a face-to-face presentation about the contents of the program, and 2) structured telephone support. The first part of the program will be conducted in the cardiology outpatient department. Participants will be instructed to read a HF handbook.~The second part of the program, structured telephone support, allowed the nurses to maintain contact with the participants in order to follow their progress. The participants will be scheduled to receive eight telephone coaching calls over a 3-month period.
Study NCT04715490 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The control group will be provided with the HF handbook at the beginning of the 3-month period, and also will be received usual care, which included medical consultations, and two telephone calls.
Study NCT02052362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-450/r/ABT-267
Description: ABT-450, ABT-267 and ritonavir
Study NCT00932256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STAHIST NDC #58407-536-01
Description: Oral tablet containing Pseudoephedrine hydrochloride 90mg, chlorpheniramine maleate 8mg, atropine sulfate .24mg, one tablet BID.
Study NCT02842866 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine
Description: 0.5 milliliter (mL), Intramuscular (IM), single dose on Day 0.
Study NCT02842866 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal Polysaccharide Vaccine, Groups A, C, Y, and W-135 Combined
Description: 0.5 mL, Subcutaneous (SC), single dose on Day 0.
Study NCT02419872 — intervention group
Intervention type: DRUG
Intervention: Marketed antagonists
Description: Medication for each patient is determined by the physician based on the patient's individual clinical profile and in accordance with the approved indication and label of the prescribed drug
Study NCT00941928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epratuzumab
Description: 360 mg/m\^2 once a day by vein on Day -4, Day -1 and Days 3, 6, 10, 13 and 17.
Study NCT00941928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m\^2 once a day by vein on Day -6 through Day -2 over 30 minutes.
Study NCT00941928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/kg once a day by vein on Days -5 and -4 over 2 hours.
Study NCT00671034 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00941928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: 12 mg/kg by vein 5 times per day on Days -5 and -4 over 15 minutes.
Study NCT00941928 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Infusion of NK cells
Description: Transplant of Haploidentical NK cells by vein on Day 0.
Study NCT00941928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Subcutaneous injections three times a week for 9 doses on Days 0 to 21.
Study NCT05460884 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Seaweed extract LD and white bread
Description: 109g of white bread with 0.5g of seaweed extract
Study NCT05460884 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Seaweed extract HD and white bread
Description: 109g of white bread with 1g of seaweed extract
Study NCT05460884 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: White bread
Description: 109g of white bread
Study NCT01944423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: d-cycloserine
Description: d-cycloserine is a medication thought to be associated with fear extinction.
Study NCT01944423 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pill Placebo
Study NCT01944423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy
Description: All participants will receive Nicoderm CQ®, 24-hour transdermal nicotine patches and will be educated about the use of the patch at the session immediately prior to quit date. They will be instructed to apply one patch daily, beginning on quit date (week 5). Participants will use the 3-step tapering Nicoderm process (21-mg, 14-mg, and 7-mg). This regimen has been used in previous trials with a similar formulation of the patch (Fiore, 2000). A meta-analysis found no differences in outcome between 16- or 24-hour patches (Fiore et al., 1994). Participants who continue to smoke or lapse after quit day will not be instructed to discontinue the patch until their smoking level reaches 4 cigarettes/day for 4 days. Smokers who lapse during treatment will be encouraged to set a new quit date and continue their cessation attempt.
Study NCT01944423 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nicotine replacement therapy
Description: All participants will receive Nicoderm CQ®, 24-hour transdermal nicotine patches and will be educated about the use of the patch at the session immediately prior to quit date. They will be instructed to apply one patch daily, beginning on quit date (week 5). Participants will use the 3-step tapering Nicoderm process (21-mg, 14-mg, and 7-mg). This regimen has been used in previous trials with a similar formulation of the patch (Fiore, 2000). A meta-analysis found no differences in outcome between 16- or 24-hour patches (Fiore et al., 1994). Participants who continue to smoke or lapse after quit day will not be instructed to discontinue the patch until their smoking level reaches 4 cigarettes/day for 4 days. Smokers who lapse during treatment will be encouraged to set a new quit date and continue their cessation attempt.
Study NCT01944423 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Panic and Smoking Reduction Treatment
Description: PSRT incorporates elements of standard smoking cessation treatment (i.e., counseling plus NRT) with procedures for reducing panic and enhancing tolerance to withdrawal sensations. Written therapist and patient manuals will be used and followed at all times to ensure standardized delivery of the treatment. Interventions that uniquely focus on addressing panic, fears and intolerance of anxiety, bodily-related sensations, and affect-relevant withdrawal symptoms include: (1) interoceptive exposure; (2) corrective information about anxiety and cognitive interventions designed to teach patients alternatives to catastrophic misinterpretations of the sensations and their feared consequences; and (3) situational exposure.
Study NCT01944423 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Panic and Smoking Reduction Treatment
Description: PSRT incorporates elements of standard smoking cessation treatment (i.e., counseling plus NRT) with procedures for reducing panic and enhancing tolerance to withdrawal sensations. Written therapist and patient manuals will be used and followed at all times to ensure standardized delivery of the treatment. Interventions that uniquely focus on addressing panic, fears and intolerance of anxiety, bodily-related sensations, and affect-relevant withdrawal symptoms include: (1) interoceptive exposure; (2) corrective information about anxiety and cognitive interventions designed to teach patients alternatives to catastrophic misinterpretations of the sensations and their feared consequences; and (3) situational exposure.
Study NCT03817528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-007
Description: ITI-007 (Lumateperone tosylate)dosed 40-60 mg based on efficacy/adverse events
Study NCT02130609 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Skintel
Study NCT04054297 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High GI/SFA diet
Description: Subject will adhere to a 2 week high GI/SFA diet.
Study NCT04054297 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low GI/SFA diet
Description: Subject will adhere to a 2 week low GI/SFA diet.
Study NCT01267279 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Zoledronic acid per protocol
Study NCT01267279 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02445469 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MRI exam of the brain
Description: MRI exam of the brain
Study NCT00671034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mercaptopurine
Description: Given PO
Study NCT00671034 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mercaptopurine
Description: Given PO
Study NCT00671034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV, IT, or PO
Study NCT00671034 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Given IV, IT, or PO
Study NCT00671034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Given IV
Study NCT00671034 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegaspargase
Description: Given IV
Study NCT00671034 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00671034 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00671034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given IV or PO
Study NCT00671034 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Given IV or PO
Study NCT00671034 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Some patients undergo RT
Study NCT00671034 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Some patients undergo RT
Study NCT00671034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioguanine
Description: Given PO
Study NCT00671034 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thioguanine
Description: Given PO
Study NCT00671034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT00671034 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Description: Given IV
Study NCT03403582 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Raspberries
Description: 250g frozen whole red raspberries
Study NCT02274571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSEC (Tissue-selective estrogen complexes)
Description: Duavee™, combination of CE(conjugated equine estrogens) and BZA (bazedoxifene)
Study NCT02274571 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TSEC (Tissue-selective estrogen complexes)
Description: Duavee™, combination of CE(conjugated equine estrogens) and BZA (bazedoxifene)
Study NCT02274571 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: non active
Study NCT02274571 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: non active
Study NCT01626924 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2-Iminobiotin
Description: 2-Iminobiotin is formulated as a 0.75 mg/ml isotonic, iso-osmotic, saline solution with a pH of 4. It is administered as a solution for I.V.infusion through a central catheter. Six pulse doses will be given in 20 hours. Dosage will starts with 0.2 mg/kg/dose, but may be adapted during the study.
Study NCT01169129 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: resection of brain metastases
Study NCT01169129 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiosurgery
Description: radiosurgery to brain metastases